Compare
Nexentis Technologies Inc. vs Jyong Biotech Ltd. vs Galectin Therapeutics Inc vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Nexentis Technologies Inc. NXTS | Jyong Biotech Ltd. MENS | Galectin Therapeutics Inc GALT | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $12.45M |
| Revenue growth (YoY) | n/a | n/a | n/a | -25.2% |
| Gross margin | n/a | n/a | n/a | 93.1% |
| Operating margin | n/a | n/a | n/a | 1.9% |
| Net margin | n/a | n/a | n/a | -60.2% |
| Net income | -$4.00M | -$4.67M | -$30.84M | -$7.49M |
| EPS (Diluted) | -$8.61 | -$0.06 | -$0.48 | -$0.12 |
| Operating cash flow | -$3.81M | -$3.04M | -$23.88M | -$11.0K |
| Free cash flow | -$3.82M | n/a | n/a | -$12.0K |
| Cash & equivalents | $3.83M | n/a | $17.72M | $2.13M |
| Total assets | $20.41M | $20.78M | $19.53M | $21.44M |
| Total liabilities | $4.67M | $45.68M | $145.73M | $85.04M |
| Shareholders' equity | $16.01M | -$24.91M | -$127.92M | -$63.61M |
| Return on year-end equity | -25.0% | n/a | n/a | n/a |
| Shares outstanding | 2.77M | 76.03M | 65.20M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Nexentis Technologies Inc. | Jyong Biotech Ltd. | Galectin Therapeutics Inc | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-12-31 | n/a | n/a | $12.45M Ended 2025-12-31 |
| 1 year earlier | $263.0K Ended 2023-12-31 | n/a | n/a | $16.65M Ended 2024-12-31 |
| 2 years earlier | $394.0K Ended 2022-12-31 | n/a | n/a | $29.60M Ended 2023-12-31 |
| 3 years earlier | $438.1K Ended 2021-12-31 | n/a | n/a | $18.39M Ended 2022-12-31 |
| 4 years earlier | $232.3K Ended 2020-12-31 | n/a | n/a | $20.61M Ended 2021-12-31 |